ARMK

Q1 2026

Date: 2026-02-10Rank: #1908Forward Promise: constructive

Aramark reported a strong start to fiscal 2026 with Q1 organic revenue growing 5% to $4.8 billion, or 8% excluding a 3% negative impact from a calendar shift. Adjusted operating income (AOI) increased 1% (11% ex-shift) to $263 million, and adjusted EPS was $0.51. Growth was broad-based, with International organic revenue up over 13% and FSS US up 2% (5% ex-shift). Key drivers included record client retention, significant new wins (Penn Medicine, RWJBarnabas Health), and double-digit growth in Workplace Experience and Refreshments. Management reaffirmed full-year guidance of 7-9% organic revenue growth, 12-17% AOI growth, and 20-25% adjusted EPS growth.

Bullishness Score

65.34

μ Mean

70.91

σ Uncertainty

1.86

Forward Promise

7.2

Management Tone

Management exhibited high confidence and enthusiasm throughout the call, frequently using superlatives like 'extraordinary,' 'unprecedented,' and 'record-breaking' to describe retention and new business wins. The tone shifted from detailed operational explanation in prepared remarks to a more defensive yet assured posture during Q&A regarding margins and cash flow, while remaining bullish on growth.

Confidence: HIGH — Management consistently reinforced guidance with specific data points on retention and pipeline, and directly addressed concerns about inflation and start-up costs without wavering on full-year targets.

Strategic Signals

Management emphasized a strategic shift in the healthcare market where clients are seeking to consolidate and systemize operations to capture cost synergies. This is evidenced by the landmark wins of Penn Medicine and RWJBarnabas Health, which CEO John Zillmer described as clients recognizing the 'need to systemize their operations.' This signals a move toward larger, more complex, integrated service contracts that leverage Aramark's enterprise-wide capabilities, potentially creating a competitive moat.

The International segment continues to be a major growth engine, delivering its 19th consecutive quarter of double-digit organic revenue growth (13%+). Management attributed this to a disciplined focus on sales resources and leadership in regions like the UK, Spain, Germany, and Chile. The success in securing mining contracts (e.g., Codelco) and sports venues (Welsh Rugby Union) indicates a successful strategy of diversifying beyond traditional food service into higher-margin, specialized sectors.

Aramark is leveraging AI and technology to drive both revenue and efficiency. On the cost side, AI is accelerating supply chain negotiations and data capture without significant incremental capital investment. On the revenue side, AI-enhanced analytics are being sold as a value-add to GPO clients. This dual-use of technology supports margin expansion (30-40 bps target) while differentiating their service offering in a competitive market.

The company is actively optimizing its capital structure, having repriced $2.4 billion of term loans to save 25 bps in interest, and continues share repurchases ($30M in Q1). This signals management's commitment to shareholder returns and financial flexibility even while investing in growth. The focus on 'disciplined organizational cost management' alongside growth investments suggests a balanced capital deployment strategy.

Key Metrics

Organic Revenue Growth5%8% ex-calendar shift

Total Revenue$4.8 BillionN/A

Adjusted Operating Income (AOI)$263 Million+1% YoY (11% ex-shift)

Adjusted EPS$0.51N/A (Impacted by shift)

Client RetentionUnprecedented/RecordHighest levels ever

FSS US Organic Growth2%5% ex-calendar shift

International Organic Growth>13%Double-digit for 19th quarter

Cash FlowOutflow$200M worse than prior year

Guidance

Organic Revenue Growth: 7% to 9%

Adjusted Operating Income Growth: 12% to 17%

Adjusted EPS Growth: 20% to 25%

Leverage Ratio: < 3.0x

Net New Business Growth: 4% to 5%

Bottom Line

Price Target: N/A

Aramark is demonstrating a successful strategic pivot, leveraging its scale to win large, integrated contracts in healthcare and international markets. The 'unprecedented' retention rates and robust pipeline of 4-5% net new business growth suggest strong momentum and pricing power. While Q1 cash flow and margins were impacted by timing and calendar shifts, the underlying operational discipline and reaffirmed guidance for double-digit EPS growth indicate a company executing well on its long-term algorithm. The shift toward cost-plus healthcare contracts also mitigates start-up risk. The risk of retention normalization remains, but management's alignment of compensation with retention and confident tone support a positive outlook.

Forward Promise

Overall: 7.2 · constructive

Confident execution backed by record retention and robust pipeline.

Management displayed high confidence in the growth trajectory, supported by specific contract wins and operational discipline, though investors should monitor cash conversion closely.

Red Flags

Q1 cash flow was significantly weaker than the prior year, with a seasonal outflow that was $200 million higher. Management attributed this to elevated CapEx (4.5% of revenue vs. 3.5% norm) due to the timing of new business wins and higher working capital needs. While management expects normalization, the increased cash burn in a quarter where revenue was impacted by a calendar shift raises questions about free cash flow conversion for the first half of the year.

Management faced scrutiny regarding the sustainability of current margins after Q1 AOI growth was just 1% (or 11% excluding the calendar shift). Analysts pressed on the 'puts and takes,' specifically regarding prior headwinds like GLP-1 drugs and medical costs. While management claims these are resolved, the reliance on calendar shift benefits in Q2 to 'normalize' margins suggests underlying profitability may be flatter than headline growth implies.

The guidance for net new business growth (4-5%) relies heavily on maintaining 'unprecedented' retention levels. While management expressed high confidence, historical reversion to the mean in retention is a risk. CEO Zillmer admitted that 'each of these decisions is independent,' and while the pipeline is robust, the loss of a few key accounts could quickly derail the net new targets given the low base of gross wins relative to retention.

There is a lack of granularity regarding the profitability of the new large-scale healthcare contracts. While management noted that healthcare contracts are often 'cost-plus' or 'cost-reimbursable' which mitigates start-up costs, this structure also inherently caps upside potential compared to fixed-price contracts. The shift toward larger, reimbursable contracts could pressure margin expansion if not perfectly executed.

Macro Insights

Consumer Behavior: Management noted 'steady as she goes' consumer trends with no pushback on pricing, supported by strong per capita spending in Sports & Entertainment and solid attendance in NBA/NHL.

Inflation: Inflation is running exactly as anticipated at ~3% for both food and labor, allowing for predictable pricing pass-throughs without margin compression.

Healthcare Industry: A strategic shift in healthcare toward consolidation and systemization to cut costs is driving large outsourcing deals (Penn, RWJBarnabas), favoring large-scale providers like Aramark.

Technology/AI: AI is viewed as a tailwind for efficiency (supply chain) and new business opportunities (data centers), rather than a labor threat, with minimal capital investment required.